Search PubMed⌕ Search

Biomedical subjects

Arjen H G Cleven

Publications and source records attributed to Arjen H G Cleven.

2 recordsLinked to original sources

Deciphering Pseudoendocrine Sarcoma: A Clinicopathological, Molecular, and Epigenetic Study Suggesting Biological Links With Solid Pseudopapillary Neoplasm of the Pancreas.

Pseudoendocrine sarcoma (PS) is a recently described neoplasm of uncertain differentiation, characterized by recurrent CTNNB1 mutations, frequent paravertebral location, and a neuroendocrine-like histomorphology. In this study, we report the clinicopathologic, immunohistochemical, transcriptomic, and epigenetic findings of 12 PS cases. The tumors affected 7 men and 5 women with a median age of 66 years and were located in the paraspinal/paravertebral region (n = 11) and the thigh (n = 1). Median tumor size was 82 mm (range, 32-170 mm). Histologically, the tumors comprised sheets and nests of epithelioid-to-ovoid cells with uniform nuclei and speckled chromatin, frequently associated with extracellular hyaline globules and fibrovascular cords/septa. Uncommon findings included microcalcifications, myxoid stroma, pseudopapillary, pseudoglandular, microcystic or corded architecture, and lumen and rosette-like structures. Necrosis was absent, and mitotic activity was low. On immunohistochemistry, the tumors showed aberrant nuclear staining for beta-catenin (8/8) and expression of CD56 (7/7), S100 (8/8), desmin (2/6), and androgen receptor (1/4). Pankeratin (AE1/AE3), progesterone receptor, synaptophysin, chromogranin, and INSM1 were negative. All tested cases harbored CTNNB1 mutations. Using a customized cohort, methylation profiling revealed that PS formed a common cluster with solid pseudopapillary neoplasm of the pancreas (SPNP), distinct from all methylation classes from the Heidelberg sarcoma classifier and a subset of paragangliomas. Transcriptomic analysis showed that PS formed an independent cluster from a control group of tumors (including SPNP). Differential gene expression analysis showed enrichment in genes of the Wnt signaling pathway (HALLMARK gene sets) and biological processes related to sensory perception, among others (gene ontology - biological process [GO-BP]). Additionally, upregulated genes were related to various fetal cell types from the cell type signature data set (MSigDB), particularly of neuronal and epithelial lineage. Immunohistochemical assessment of potential markers identified through gene expression analysis revealed focal-to-diffuse expression of GLUT1 (6/6) and focal/multifocal expression of Brachyury (4/9) and HuD (3/7). Follow-up information, available for 10 cases (median duration of 18 months; range, 7-69 months), showed local recurrences and metastatic spread in 2 patients each. Evidence of response to radiotherapy was documented in one tumor. Altogether, this study expands knowledge on PS and suggests biological links with SPNP, including a potential shared cell of origin.

Humans↗

Cardiovascular outcome stratification using the ankle-brachial pressure index.

OBJECTIVES: To investigate, in patients with peripheral arterial disease (PAD), the association between the level of the Ankle-Brachial Pressure Index (ABPI) at time of diagnosis and clinical outcome. METHODS: The data set of the Limburg PAOD Longitudinal Study (n=3649, mean follow-up time 7.2 years) was analyzed for this purpose. The ABPI was measured by trained personnel using handheld Doppler devices. Subjects were classified into 6 baseline ABPI categories ranging from ABPI > or = 1.10 ('certainly normal') to ABPI<0.50 ('seriously reduced'). Outcome measures were progressive limb ischaemia, cardiovascular morbidity and cardiovascular mortality. Cox proportional hazard models were used to investigate the associations (including hazard ratio's, HR) between different ABPI categories and outcome events. RESULTS: As compared to persons with an ABPI > or = 1.10 ('certainly normal'), patients with a baseline ABPI <1.00 (categories 'probably normal' and worse) were at high risk to develop progressive limb ischaemia (HR 3.3 - 9.0). Additionally, patients with a baseline ABPI <0.90 (categories 'moderately reduced' and worse) were at higher risk to experience a non-fatal cardiovascular disease (HR 1.5 - 1.7). Moreover, patients with a baseline ABPI <0.70 ('clearly' and 'seriously' reduced ABPI) were at high risk to die from a cardiovascular or other cause (HR 2.3). CONCLUSION: The ABPI can be helpful in identifying subjects at high risk for a poor cardiovascular outcome, in whom strict cardiovascular risk management would be appropriate.

Adult↗